Analysts Set Avantor, Inc. (NYSE:AVTR) PT at $26.15

Shares of Avantor, Inc. (NYSE:AVTR) have received a consensus rating of “Moderate Buy” from the twelve research firms that are covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $25.92.

Several research firms have weighed in on AVTR. UBS Group restated a “neutral” rating and set a $25.00 target price (down from $29.00) on shares of Avantor in a report on Friday, January 17th. Barclays decreased their price target on shares of Avantor from $26.00 to $23.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. Stifel Nicolaus decreased their price target on shares of Avantor from $28.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday, February 10th. Raymond James reaffirmed an “outperform” rating and set a $24.00 price target (down from $26.00) on shares of Avantor in a research note on Monday, February 10th. Finally, Royal Bank of Canada decreased their price target on shares of Avantor from $33.00 to $31.00 and set an “outperform” rating on the stock in a research note on Monday, February 10th.

Avantor Stock Performance

NYSE:AVTR opened at $17.52 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.70 and a debt-to-equity ratio of 0.54. The firm has a 50-day moving average price of $21.06 and a two-hundred day moving average price of $23.01. Avantor has a twelve month low of $17.14 and a twelve month high of $28.00. The company has a market capitalization of $11.93 billion, a P/E ratio of 16.84, a price-to-earnings-growth ratio of 1.56 and a beta of 1.28.

Avantor (NYSE:AVTR) last posted its earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.01. Avantor had a net margin of 10.49% and a return on equity of 12.17%. During the same quarter in the prior year, the company posted $0.22 earnings per share. As a group, research analysts expect that Avantor will post 1.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Avantor

Hedge funds have recently modified their holdings of the stock. Public Employees Retirement System of Ohio boosted its position in shares of Avantor by 34.1% in the third quarter. Public Employees Retirement System of Ohio now owns 346,822 shares of the company’s stock worth $8,972,000 after acquiring an additional 88,205 shares during the last quarter. Perpetual Ltd lifted its position in Avantor by 38.7% during the fourth quarter. Perpetual Ltd now owns 1,766,882 shares of the company’s stock valued at $37,228,000 after buying an additional 493,408 shares in the last quarter. New York State Teachers Retirement System acquired a new position in Avantor during the third quarter valued at approximately $8,473,000. Everence Capital Management Inc. acquired a new position in Avantor during the fourth quarter valued at approximately $555,000. Finally, Teachers Retirement System of The State of Kentucky lifted its position in Avantor by 45.8% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 723,178 shares of the company’s stock valued at $18,708,000 after buying an additional 227,200 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.